Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Wally R. Smith, Swee Lay Thein et al.|The Lancet Haematology|2024Cited by 25
Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatmentHanny Al‐Samkari, Eduard J. van Beers, Rachael F. Grace et al.|Haematologica|2023Cited by 2